- Conditions
- Cytomegalovirus Infection
- Interventions
- MBX400, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 2,369
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- ABT-072, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Abbott Park, Illinois
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Carbohydrate-restricted diet, Mindfulness
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy Volunteers
- Interventions
- Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Interventions
- α-lactalbumin vaccine, Zymosan
- Biological
- Lead sponsor
- George T. Budd
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Obesity, Prader Willi Syndrome
- Interventions
- High carbohydrate meal, High fat meal
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Amino Acids
- Interventions
- ProHydrolase®, Whey protein, Placebo
- Dietary Supplement
- Lead sponsor
- Deerland Enzymes
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
- Interventions
- External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
- Radiation · Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Lactose Intolerance
- Interventions
- RP-G28, Placebos
- Drug
- Lead sponsor
- Ritter Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Chula Vista, California • Huntington Park, California + 31 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Interventions
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- digitoxin, placebo
- Drug · Other
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Fanconi Anemia
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, Hematopoietic stem cell transplantation
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Spinal Cord, Metabolic Syndrome, Diabetes
- Interventions
- LC/HP
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
- Conditions
- Multiple Myeloma
- Interventions
- Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan, Leukapheresis, Myeloma vaccine, GM-CSF, Lenalidomide
- Procedure · Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 11 more
- Conditions
- Obese, Disorder of Vitamin C, Growth Hormone Secretion Abnormality
- Interventions
- Placebo, Vitamin C 250 mg once daily, Vitamin C 1,000 mg once daily
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Obstructive Pulmonary Disease, Aging
- Interventions
- Fiber Inulin, Placebo Maltodextrin
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Low Back Pain, Back Pain With Radiation, Back Pain Without Radiation, Back Pain Lower Back Chronic, Back Ache, Pain, Chronic
- Interventions
- Minocycline Hydrochloride 100mg Capsule, Magnetic Resonance-Positron Emission Tomography Imaging, Placebo Capsule
- Drug · Diagnostic Test · Other
- Lead sponsor
- Marco Loggia
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, melphalan, pamidronate disodium, thalidomide, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2018
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Hepatic Encephalopathy
- Interventions
- Fecal Microbiota Transplant (FMT) oral capsules, Placebo oral capsule
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Meniscectomy, Osteoarthritis
- Interventions
- NUsurface® Meniscus Implant, NSAID's and Non-surgical Treatment Options, Intra-Articular Injections with Corticosteroids, Intra-Articular Injections with Hyaluronic Acid (HA)
- Device · Drug
- Lead sponsor
- Phoenix Kinetics
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Roxbury Crossing, Massachusetts + 6 more
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
- Conditions
- Malignant Glioma, High Grade Glioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida